Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Meta-analysis: anti-BCMA CAR-T in R/R multiple myeloma

Nico Gagelmann • 26 Aug 2020
EBMT 2020
Multiple Myeloma CAR-T

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from a meta-analysis evaluating the outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nico Gagelmann

The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T 0:52
The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
Nico Gagelmann • 7 Feb 2025
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma 1:04
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
Nico Gagelmann • 7 Feb 2025
Addressing equity and equality in access to CAR-T in Europe 1:08
Addressing equity and equality in access to CAR-T in Europe
Nico Gagelmann • 7 Feb 2025
How CAR-T will impact the future of myeloma treatment 0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals